セッション一覧

TBD

We hear about DX in the media, inside our copanys, and everywhere else, and digital is being used to interact with physicians in commercial activitys. In this session, we will discuss what DX is, what the goals of DX are, and what mindset and actions are required for each person involved in DX? This session will provide insights from outside of the pharmaceutical, as well as implications for those working on DX from leaders inside and outside the pharmaceutical industry.

Pharmaceutical companies are lagging behind the general industry in digital marketing, but we think that existing channels are abundant.
Here, we would like to share the utilization status of the customer's action data and the results of timely communication.

Why are "people" and "organizations" the key to change? We will look back at the environment surrounding us and the recent changes in people and organizations.
What has advanced and what has stagnated in DX in commercial activities? What needs to be accelerated in the future?
We plan to have an interactive session with the participants.

We have been discussing and debating about multi-channel activities and their management with the members of V-Katsu! This presentation will summarize the multichannel sales activities and their management that we have been discussing and debating with our members at V-Katsu!

As pandemic continues, new attempts are being made to communicate with physicians, mainly through digital, but at the same time, new challenges are found. Through the discussion with physicians , we will provide implications of "the essence of communication" to Pharma marketers.

We will look back on the basic usage from the introduction of PromoMats in Astellas, and then introduce the effective and efficient utilization, owned media integration, and evolution to globalization.

It has been a year in which the people in charge of front-line activities, as well as those who plan and support those activities, have had to respond to changes most quickly in the organization.
In order to get them to respond to these changes in the field, I am sure they have accumulated a variety of experiences, some of which did not go well and some of which brought better results than expected. In this session, I would like to share various experiences with the participants and have an active discussion where we can freely exchange opinions on what we can do in the next year.

We will share issues such as platforms for data utilization and involvement of MRs that are necessary for omni-channel promotion, and discuss actions necessary to realize a field-driven omni-channel.

TBD

TBD

From 2020 onwards, due to the spread of new coronavirus infections, MSD's promotional activities are undergoing major changes in both acute and chronic areas. We are aiming to develop our business by rapidly moving our promotional activities to remote locations (remote interviews/lectures) and building a new customer engagement model that utilizes rapid data maintenance and data. This presentation will introduce the efforts and challenges in these activities.

TBD

Due to changes in the business environment surrounding pharmaceutical wholesalers, pharmaceutical wholesalers are under pressure to change their business style.
There are many changes in the environment that are imposed on the distribution and sales of pharmaceutical wholesalers such as annual drug price revisions, drug category changes, sales information provision activity guidelines, and proper drug distribution (GDP).
In addition, the new issue of drug distribution under the situation of COVID-19 has brought upon an opportunity to fundamentally review not only logistics but also the way information is provided.
There are high expectations for Veeva to build an information supply chain to function as an information hub.

The way we provide information to our customers is changing drastically, and many of us are facing challenges in the channels we use as well as the information we convey and how we convey it. In this interactive session, we would like to discuss how to solve these issues and what is required of marketing departments to solve them.

There is no doubt that our business model is diversified such as Oncology, Rare Disease, Personalized Medicine and so on. Through the discussion at this session, it is expected to share our facing challenges to seek for best/better MCCM approach in the future.

TBD

Please check out our future roadmap for respective commercial products including Veeva CRM.

The activities of Reps have changed drastically. The use of digital is expanding. However, it is difficult to build relationships with HCP through digital alone, and now the key is to combine the digital with the real. This session will introduce how Veeva Commercial Cloud can support "Hybrid MR".

Introducing the background, goals and value of Veeva Business consulting that launched this year.